Cerus Stock Forecast, Price & News

-0.05 (-0.84 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.11 million shs
Average Volume2.04 million shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

Cerus logo

About Cerus

Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.74 out of 5 stars

Medical Sector

244th out of 2,100 stocks

Surgical & Medical Instruments Industry

22nd out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cerus (NASDAQ:CERS) Frequently Asked Questions

Is Cerus a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cerus stock.
View analyst ratings for Cerus
or view top-rated stocks.

What stocks does MarketBeat like better than Cerus?

Wall Street analysts have given Cerus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cerus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cerus' next earnings date?

Cerus is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Cerus

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings results on Tuesday, May, 4th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The biotechnology company earned $23.38 million during the quarter, compared to analyst estimates of $21.50 million. Cerus had a negative trailing twelve-month return on equity of 57.92% and a negative net margin of 62.93%.
View Cerus' earnings history

How has Cerus' stock been impacted by COVID-19?

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERS shares have increased by 23.7% and is now trading at $5.89.
View which stocks have been most impacted by COVID-19

What guidance has Cerus issued on next quarter's earnings?

Cerus updated its FY 2021 earnings guidance on Tuesday, May, 25th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $110 million-$114 million, compared to the consensus revenue estimate of $130.95 million.

What price target have analysts set for CERS?

1 equities research analysts have issued 12 month price targets for Cerus' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Cerus' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 52.8% from the stock's current price.
View analysts' price targets for Cerus
or view top-rated stocks among Wall Street analysts.

Who are Cerus' key executives?

Cerus' management team includes the following people:
  • Obi Greenman, President, Chief Executive Officer & Director
  • Vivek K. Jayaraman, Chief Operating Officer
  • Kevin Dennis Green, Chief Financial Officer & Vice President-Finance
  • Laurence M. Corash, Chief Scientific Officer
  • Carol M. Moore, Senior VP-Regulatory Affairs, Quality & Clinical

What is William M. (Obi) Greenman's approval rating as Cerus' CEO?

15 employees have rated Cerus CEO William M. (Obi) Greenman on William M. (Obi) Greenman has an approval rating of 35% among Cerus' employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (14.92%), Nikko Asset Management Americas Inc. (7.84%), Sumitomo Mitsui Trust Holdings Inc. (7.77%), BlackRock Inc. (7.41%), Primecap Management Co. CA (5.95%) and Wasatch Advisors Inc. (3.52%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends for Cerus

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, D. E. Shaw & Co. Inc., Sepio Capital LP, Morgan Stanley, Millennium Management LLC, Primecap Management Co. CA, Cubist Systematic Strategies LLC, and SG Americas Securities LLC. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Vivek K Jayaraman, and William Mariner Greenman.
View insider buying and selling activity for Cerus
or view top insider-selling stocks.

Which institutional investors are buying Cerus stock?

CERS stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Kennedy Capital Management Inc., Paradigm Capital Management Inc. NY, Pier Capital LLC, BlackRock Inc., and Geode Capital Management LLC.
View insider buying and selling activity for Cerus
or or view top insider-buying stocks.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $5.89.

How much money does Cerus make?

Cerus has a market capitalization of $1.01 billion and generates $91.92 million in revenue each year. The biotechnology company earns $-59,860,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does Cerus have?

Cerus employs 254 workers across the globe.

What is Cerus' official website?

The official website for Cerus is

Where are Cerus' headquarters?

Cerus is headquartered at 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at (925) 288-6000 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.